These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 6480380

  • 1. Evaluation of estrogen dependency of human breast cancers. II. Clinical evaluation of tamoxifen in advanced primary and recurrent breast cancer.
    Nishiki M, Yamane M, Amano K, Yasuda K, Okumichi T, Ezaki H.
    Hiroshima J Med Sci; 1984 Jun; 33(2):163-6. PubMed ID: 6480380
    [No Abstract] [Full Text] [Related]

  • 2. [Tamoxifen therapy in locally advanced primary and recurrent breast cancer (author's transl)].
    Wada T, Koyama H, Takahashi Y, Nishizawa Y, Iwanaga T, Aoki Y, Terasawa T.
    Nihon Gan Chiryo Gakkai Shi; 1979 Aug 20; 14(5):819-24. PubMed ID: 501187
    [No Abstract] [Full Text] [Related]

  • 3. [Tamoxifen: modern drug therapy of estrogen-dependent breast tumors].
    Jovanović-Mićić D, Beleslin DB, Nikolić SS.
    Med Pregl; 1996 Aug 20; 49(7-8):287-90. PubMed ID: 8926945
    [Abstract] [Full Text] [Related]

  • 4. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M, Kodama T.
    In Vivo; 2001 Aug 20; 15(4):319-25. PubMed ID: 11695224
    [Abstract] [Full Text] [Related]

  • 5. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.
    Breast Cancer Res; 2008 Aug 20; 10(5):R88. PubMed ID: 18928543
    [Abstract] [Full Text] [Related]

  • 6. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE.
    Cancer; 2004 Sep 15; 101(6):1311-22. PubMed ID: 15368322
    [Abstract] [Full Text] [Related]

  • 7. Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum Her-2/neu levels: question of tamoxifen resistance.
    Altundag K, Altundag O.
    J Clin Oncol; 2003 Dec 15; 21(24):4656; author reply 4657. PubMed ID: 14673060
    [No Abstract] [Full Text] [Related]

  • 8. [Results of anti-estrogen therapy in metastatic breast cancer (preliminary results). Part II].
    Firusian N, Schmidt CG.
    Med Welt; 1977 Dec 30; 28(51-52):2065-7. PubMed ID: 414049
    [No Abstract] [Full Text] [Related]

  • 9. Physicians' assessments of adjuvant tamoxifen's effectiveness in older patients with primary breast cancer.
    Lash TL, Gurwitz JH, Silliman RA.
    J Am Geriatr Soc; 2005 Nov 30; 53(11):1889-96. PubMed ID: 16274369
    [Abstract] [Full Text] [Related]

  • 10. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
    Newby JC, Johnston SR, Smith IE, Dowsett M.
    Clin Cancer Res; 1997 Sep 30; 3(9):1643-51. PubMed ID: 9815855
    [Abstract] [Full Text] [Related]

  • 11. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
    Meijer-van Gelder ME, Look MP, Peters HA, Schmitt M, Brünner N, Harbeck N, Klijn JG, Foekens JA.
    Cancer Res; 2004 Jul 01; 64(13):4563-8. PubMed ID: 15231667
    [Abstract] [Full Text] [Related]

  • 12. [Superiority of letrozole compared with tamoxifen as first line therapy of postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group].
    Illiger HJ.
    Strahlenther Onkol; 2002 Feb 01; 178(2):111-3. PubMed ID: 11942036
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy.
    Toi M, Ikeda T, Akiyama F, Kurosumi M, Tsuda H, Sakamoto G, Abe O.
    Int J Oncol; 2007 Oct 01; 31(4):899-906. PubMed ID: 17786323
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.